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Objectives This study sought to ascertain if high-dose allopurinol regresses left ventricular mass (LVM) in patients with isch-
emic heart disease (IHD).
Background LV hypertrophy (LVH) is common in patients with IHD including normotensive patients. Allopurinol, a xanthine
oxidase inhibitor, has been shown to reduce LV afterload in IHD and may therefore also regress LVH.
Methods A randomized, double-blind, placebo-controlled, parallel group study was conducted in 66 patients with IHD and
LVH, comparing 600 mg/day allopurinol versus placebo therapy for 9 months. The primary outcome measure
was change in LVM, assessed by cardiac magnetic resonance imaging (CMR). Secondary outcome measures
were changes in LV volumes by CMR, changes in endothelial function by flow-mediated dilation (FMD), and arte-
rial stiffness by applanation tonometry.
Results Compared to placebo, allopurinol significantly reduced LVM (allopurinol 5.2  5.8 g vs. placebo 1.3  4.48 g;
p  0.007) and LVM index (LVMI) (allopurinol 2.2  2.78 g/m2 vs. placebo 0.53  2.5 g/m2; p  0.023). The
absolute mean difference between groups for change in LVM and LVMI was 3.89 g (95% confidence interval: 1.1
to 6.7) and 1.67 g/m2 (95% confidence interval: 0.23 to 3.1), respectively. Allopurinol also reduced LV end-
systolic volume (allopurinol 2.81  7.8 mls vs. placebo 1.3  7.22 mls; p  0.047), improved FMD (allopurinol
0.82  1.8% vs. placebo 0.69  2.8%; p  0.017) and augmentation index (allopurinol 2.8  5.1% vs. placebo
0.9  7%; p  0.02).
Conclusions High-dose allopurinol regresses LVH, reduces LV end-systolic volume, and improves endothelial function in pa-
tients with IHD and LVH. This raises the possibility that allopurinol might reduce future cardiovascular events and
mortality in these patients. (Does a Drug Allopurinol Reduce Heart Muscle Mass and Improve Blood Vessel Func-
tion in Patients With Normal Blood Pressure and Stable Angina?; ISRCTN73579730) (J Am Coll Cardiol 2013;
61:926–32) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.066Cardiovascular disease is the most common cause of death
in the western world. Most of the attention in treating
ischemic heart disease (IHD) is understandably directed
toward treating coronary artery disease. However there are
other treatable culprits in these patients.
Left ventricular hypertrophy (LVH) is widespread in
IHD patients, even in the absence of hypertension (1). It is
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2012, accepted September 16, 2012.a strong predictor of cardiovascular events and all-cause
mortality (2). In one study, the presence of LVH was a
stronger predictor of mortality than either multivessel cor-
onary disease or impaired LV function (3). The reason why
LVH is so adverse is because it predates many different
cardiovascular events (i.e., LVH is arrhythmogenic and
causes sudden death, impedes LV filling and leads to
diastolic heart failure, reduces coronary perfusion reserve,
and causes left atrial enlargement, atrial fibrillation, and
See page 933
cardioembolic strokes) (4). Regression of LVH has been
associated with an improved prognosis, independent of
change in blood pressure (BP) (5–7). Therefore, cardiovas-
cular events and mortality in IHD might well be reduced if
we can find novel therapies to regress LVH.
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March 5, 2013:926–32 Allopurinol and LVH in Ischemic Heart DiseaseAllopurinol, a xanthine oxidase inhibitor, may regress left
ventricular mass (LVM) in IHD patients for a number of
reasons. First, xanthine oxidase inhibitors have been shown
to regress LVM in several animal models (8–10). Second, a
recent human study has shown allopurinol to regress LVM
in chronic kidney disease patients (11). Third, allopurinol
may also regress LVM because it reduces augmentation index in
patients with IHD, thereby reducing LV afterload (12).
Hence, the main aim of this study was to assess whether
allopurinol could regress LVM in patients on optimal, current
evidence-based therapy for IHD. The secondary aim was to
assess the effect of allopurinol on LV volumes, endothelial
function, and arterial stiffness in this patient group.
Methods
Study overview. This was a randomized, double-blind,
placebo controlled, parallel group study using a 9-month
treatment period at a single center in Dundee, Scotland. It
was approved by the Tayside Research Ethics Committee
and was done in accordance with the Declaration of
Helsinki. All patients provided written informed consent.
This study has been registered with the International
Standard Randomized Controlled Trial Number register
ISRCTN73579730.
Study participants. Sixty-six adult patients were recruited
from hospital cardiology databases and local general prac-
tices. They had to have either angiographically documented
coronary artery disease (80%) or a previous history of
myocardial infarction (12%), or both typical symptoms of
angina and a positive stress test for ischemia (8%). In the
latter group, the stress test was an exercise tolerance test in
3 patients and a nuclear myocardial perfusion scan in 2
patients. They were also required to have an office BP
150/90 mm Hg and the presence of LVH on echocardi-
ography (American Society of Echocardiography criteria
LVM index [LVMI]115 g/m2 for men and95 g/m2 for
omen) (13). Patients were excluded if they were currently
rescribed allopurinol or azathioprine, had a previous ad-
erse reaction to allopurinol, or active gout. They were also
xcluded if they had renal dysfunction (glomerular filtration
ate  60 ml/min), heart failure, or malignancy, or were
nable to give informed consent. Patients with contraindi-
ations to cardiac magnetic resonance (CMR) (pacemakers,
laustrophobia) were also excluded, as were pregnant or
actating women.
andomization and masking. Baseline assessments and
nvestigations (blood tests, flow-mediated dilation [FMD]
f the brachial artery in response to hyperemia, applanation
onometry, CMR) were performed followed by randomiza-
ion by a computer-generated random allocation sequence.
atients were randomly assigned to receive either allopuri-
ol 100 mg/day or placebo for 2 weeks. If this was tolerated,
he trial medication dosage was increased to allopurinol
00 mg/day for a month. After 1 month of treatment, the
osage was increased to 300 mg twice daily of allopurinol or mlacebo therapy for a further 7.5
onths. Blood tests were taken
t baseline and final visit for full
lood count, renal function, liver
unction, uric acid, B-type natri-
retic peptide (BNP) and oxidized
ow-density lipoprotein. Office BP
as measured for all the patients at
ach visit (2, 6, 10, 28, and 39
eeks) by the same blinded inves-
igator after the subject had rested
or at least 10 min. Furthermore,
2 randomly selected patients had
24–h BP ambulatory monitor at
aseline and final visit. During the
tudy, all patients continued their
oncomitant medication.
ardiacmagnetic resonance imag-
ng. Cardiac magnetic resonance
maging was performed at base-
ine and at 9 months on a 3T Magnetom Trio scanner
Siemens, Erlangen, Germany) using body array and spine
atrix radiofrequency coils as described in detail by us
reviously (11). CMR images were analyzed offline by an
ndependent, blinded magnetic resonance imaging (MRI)
hysicist (S.J.G.) using commercial software (Argus, Sie-
ens Multi-modality Work Platform, version VB 15,
iemens of Erlangen, Germany). Electronic region of in-
erest contours were placed around endocardial and epicar-
ial LV borders on all CMR image slices at end-diastole
nd end-systole that were identified to contain 50% or more
ull-thickness myocardium. Papillary muscles were included
n the LVM if the muscle structure was indistinguishable
rom the myocardial wall, but otherwise assigned to the LV
lood pool. The process of contour placement was repeated
uch that every patient dataset at both time points was
nalyzed twice in order to optimize the measurement
recision.
MD. Endothelial function was assessed by measuring
MD of the brachial artery in response to hyperemia as set
ut in the International Brachial Artery Reactivity Task
orce guidelines and as performed regularly at our institute
12,14,15). FMD was performed at the baseline visit, 6
onths, and 9 months using a Sequoia 512 (Siemens,
amberley, England) ultrasound machine with a 8 MHz
inear array probe. The FMD was analyzed using Vascular
esearch Tools software (Medical Imaging Applications
LC, Coralville, Iowa). The acquisition and analyses of the
MD images were performed by a single trained investiga-
or (S.R.), who was blinded to the allocated treatment.
pplanation tonometry. Pulse wave analysis and pulse
ave velocity (PWV) were measured at baseline, 6 months
isit, and 9 months visit using the validated Sphygmocor
AtCor, Sydney, Australia) system by a single trained
nvestigator (S.R.) who was blinded to the allocated treat-
Abbreviations
and Acronyms
AIx  augmentation index
BNP  B-type natriuretic
peptide
BP  blood pressure
CMR  cardiac magnetic
resonance
FMD  flow-mediated
dilation
IHD  ischemic heart
disease
LVH  left ventricular
hypertrophy
LVM  left ventricular
mass
LVMI  left ventricular
mass index
PWV  pulse wave velocityent. This technique is in widespread use in our institute
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Allopurinol and LVH in Ischemic Heart Disease March 5, 2013:926–32and our methodology was as described subsequently (12).
From the aortic pulse wave, augmentation index (AIx) was
calculated as the difference between the first and second
systolic peak expressed as a percentage of the pulse pressure.
As AIx is affected by heart rate, AIx was normalized for a
heart rate of 75 beats/min. For PWV, radial-carotid wave-
forms were obtained with electrocardiogram gating.
Statistical analysis. The primary endpoint was LVM on
MR. We followed the recommendations of Grothues et
l. (16), which advised that 30 patients would be needed to
etect a 10-g change in LVM at 90% power, on the basis of
reproducibility figure of 3.6%. In fact, we doubled our
umbers to 60 patients and then to 66 patients to account
or 10% dropouts. We doubled our numbers because we
hought 30 patients was a bit tight and because it would be
hallenging to regress LVM by 10 g in only 9 months with
o expected change in BP. Using Grothues et al. reproduc-
bility figure, our 60 patients study had 90% power to detect
5-g change in LVM. We were also aware that this figure
atched the differential change in LVMI between the treat-
ents in the echo substudy of the LIFE (Losartan Interven-
ion For Endpoint reduction in hypertension) study (7).
Data for continuous variables are presented as mean 
D for normally distributed data and median and interquar-
ile range for non-normally distributed data. Categorical
ata are expressed as numbers (%). Comparisons between
 
Figure 1 Flow Diagram of the Study
CMR  cardiac magnetic resonance; LVH  left ventricular hypertrophy.ontinuous variables were analyzed using the Student t testor Mann-Whitney U test while categorical variables were
analyzed using chi-square test. Correlation was performed
using Pearson’s or Spearman’s method.
All statistical analyses were undertaken using SPSS ver-
sion 18.0 (SPSS, Chicago, Illinois). A 2-sided p value
0.05 was considered statistically significant.
Results
A total of 66 patients were recruited for this study. Only 1
patient had ever before received allopurinol (27 months
earlier). As there were 6 study dropouts (allopurinol n  2,
placebo n  4), 60 underwent FMD and applanation tonom-
etry while 55 patients completed CMR (Fig. 1, Table 1).
Treatment with high-dose allopurinol significantly re-
duced LVM (change in LVM: allopurinol group 5.2 
5.8 g vs. placebo group 1.3  4.48 g; p  0.007) and
LVMI (change in LVMI: allopurinol group 2.2  2.78
g/m2 vs. placebo group0.53 2.5 g/m2; p 0.023) (Fig. 2).
he absolute mean difference between the groups for
hange in LVM was 3.89 g (95% confidence interval:
1.1 to 6.7) and 1.67 g/m2 (95% confidence interval:
0.23 to 3.1) for change in LVMI. The change in LVM
in the allopurinol group remained statistically significant
even after correcting for baseline LVM (p 0.013). Fur-
thermore, the within-group changes in LVM and LVMI
   z          were significant in the allopurinol group (p  0.001 for
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March 5, 2013:926–32 Allopurinol and LVH in Ischemic Heart Diseaseboth) but not in the placebo group (Table 2). We found no
significant differences in the allopurinol-induced change in
either LVM or LVMI (p 0.15 and p 0.25, respectively)
etween those with a past history of MI versus those
Baseline Characteristics of Study ParticipantsTable 1 Baseline Characteristics of Study Participants
Allopurinol
(n  31)
Placebo
(n  29)
p
Value
Age, yrs 65 6.7 64 7.2 0.64
Male 26 (84%) 28 (97%) 0.1
BSA, g/m2 2.05 0.18 2.0 0.2 0.26
Office SBP, mm Hg 135 9 134 10 0.87
24-h SBP, mm Hg 124 11 121 9 0.42
Office DBP, mm Hg 78 6.8 76 7 0.26
24-h DBP, mm Hg 70 5 74 5 0.06
Past MI 13 (42%) 17 (59%) 0.2
Hypertension 23 (74%) 16 (55%) 0.12
Diabetes 4 (13%) 3 (10%) 0.8
Cerebrovascular disease 4 (13%) 2 (7%) 0.4
Peripheral vascular disease 3 (9.7%) 2 (7%) 0.7
Smoking 0.24
Non 7 (22.6%) 12 (41%)
Ex 19 (61.3%) 12 (41%)
Current 5 (16.1%) 5 (17%)
CCS classification 0.88
1 23 (74%) 21 (72%)
2 8 (26%) 8 (28%)
Positive stress test in those
without angiogram/
previous MI
3 (9.7%) 2 (6.9%) 0.17
No. of vessel disease 0.047
1 2 (7%) 12 (41%)
2 11 (36%) 8 (28%)
3 9 (29%) 6 (21%)
PCI 6 (19%) 15 (52%) 0.01
CABG 15 (48%) 8 (28%) 0.1
Aspirin 26 (83.9%) 29 (100%) 0.024
Clopidogrel 4 (12.9%) 4 (14%) 0.94
Statin 29 (93.5%) 27 (93%) 0.916
Ezetimibe 3 (9.7%) 2 (7%) 0.7
Beta-blocker 24 (77.4%) 18 (62%) 0.2
Calcium-channel blocker 10 (32.3%) 13 (45%) 0.3
Nicorandil 2 (6.5%) 6 (21%) 0.1
Isosorbide mononitrate 9 (29%) 11 (38%) 0.47
ACE inhibitor 20 (64.5%) 15 (52%) 0.32
ARB 7 (22.6%) 3 (10%) 0.2
Uric acid, mmol/l 0.59 0.09 0.56 0.14 0.326
BNP, pg/ml 31.0 (21–60) 20.6 (13–35) 0.026
FMD 4.1 2.1 5.68 2.4 0.01
AIx 20 7 19.5 9 0.73
PWV, m/s 7.6 (6.9 to 8.7) 8.5 (7.4 to 9) 0.022
CMR LVM, g 145.7 23.4 136.4 26 0.17
CMR LVMI, g/m2 70.98 9 68.39 11.14 0.347
Values are mean  SD, n (%), or median (interquartile range).
ACE inhibitor  angiotensin-converting enzyme inhibitor; AIx  augmentation index; ARB 
ngiotensin receptor blocker; BNP B-type natriuretic peptide; BSA body surface area; CABG
coronary artery bypass grafting; CCS Canadian Cardiovascular Society; CMR cardiac magnetic
resonance; DBP  diastolic blood pressure; FMD  flow mediated dilation; LVM  left ventricular
mass; LVMI  left ventricular mass index; MI  myocardial infarction; PCI  percutaneous
coronary intervention; PWV  pulse wave velocity; SBP  systolic blood pressure.ithout a past history of MI. vAllopurinol also significantly reduced LV end-systolic
olume (allopurinol group 2.81  7.8 mls vs. placebo
roup 1.3  7.22 mls; p  0.047) and nonsignificantly
educed LV end-diastolic volume (allopurinol group 6.05 
6.42 mls vs. placebo group 0.48  16.87 mls; p  0.15)
(Table 2). Allopurinol was associated with a reduction in
median BNP just short of statistical significance (allopurinol
Figure 2 Effect of Allopurinol on Change in LVMI and LVM
(A) This graph illustrates the effect of 9 months of allopurinol or placebo treat-
ment on the change in LVMI. Allopurinol significantly reduced LVMI after 9
months of therapy compared with placebo (p  0.023). Data are expressed as
mean  SEM. (B) This graph illustrates the effect of 9 months of allopurinol or
placebo treatment on the change in LVM. Allopurinol significantly reduced LVM
after 9 months of therapy compared with placebo (p  0.007). Data are
expressed as mean  SEM.
CMR Changes Seen After Allopurinol TreatmentTable 2 CMR Changes Seen After Allopurinol Treatment
Allopurinol
(n  27)
Placebo
(n  28) p Value
Change in LVM, g 5.2 5.8 1.3 4.48 0.007
Change in LVMI, g/m2 2.2 2.78 0.53 2.5 0.023
% change in LVM 3.57 3.98 0.98 3.29 0.01
% change in LVMI 3.29 4.29 0.85 3.7 0.028
Change in EF, % 0.58 3.27 0.61 3.71 0.24
Change in EDV, mls 6.05 16.42 0.48 16.87 0.15
Change in ESV, mls 2.81 7.8 1.3 7.22 0.047
Change in SV, mls 3.28 12.78 0.81 13.25 0.49
Change in CO, l/min 0.085 0.93 0.11 0.89 0.44
Values are mean  SD.
CO  cardiac output; EDV  end-diastolic volume; EF  ejection fraction; ESV  end-systolic
olume; SV  stroke volume; other abbreviations as in Table 1.
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Allopurinol and LVH in Ischemic Heart Disease March 5, 2013:926–32group5.5 pg/ml [19 to 5 pg/ml], placebo group1.1 pg/ml
[7 to 5 pg/ml]; p  0.08).
At baseline, brachial artery size was similar between the
roups but there was a significant difference in baseline
MD (allopurinol group 4.1  2.1% vs. placebo group
.68  2.4%; p  0.01). However, allopurinol improved
MD, which was significant at 9 months (change in FMD
llopurinol group: 0.82  1.8% vs. placebo 0.69  2.8%;
p  0.017) (Fig. 3, Table 3). Within the allopurinol group,
MD changes were also significant (p  0.019), whereas
his was not the case in the placebo group. Interestingly,
llopurinol significantly reduced the response to GTN
ompared to placebo, which agrees with some recent data
ut not with others (12,17). Allopurinol also significantly
educed AIx, which was statistically significant at 9 months.
ithin the allopurinol group itself, AIx changes were
Figure 3 Effect of Allopurinol on the Change in FMD
This graph illustrates the effect of 6 months and 9 months of allopurinol (trian-
gles) or placebo (squares) treatment on the change in flow-mediated dilation
(FMD). Allopurinol significantly improved FMD after 9 months of therapy com-
pared with placebo (p  0.017). Data are expressed as mean  SEM.
Effect of Allopurinol on Hemodynamics and EndoTable 3 Effect of Allopurinol on Hemodynam
Change in office SBP, mm Hg
Change in office DBP, mm Hg
Change in 24-h SBP, mm Hg
Change in 24-h DBP, mm Hg
Change in FMD response to hyperemia at 6 months, %
Change in FMD response to hyperemia at 9 months, %
Change in response to GTN at 6 months, %
Change in response to GTN at 9 months, %
Change in AIx at 6 months, %
Change in AIx at 9 months, %
Change in PWV at 6 months, m/s
Change in PWV at 9 months, m/sValues are mean  SD or median (interquartile range).
Abbreviations as in Table 1.ignificant (p  0.004), while this was not the case within
he placebo group (Table 3, Fig. 4).
Allopurinol did not have any significant effect on office
P or 24-h ambulatory BP (Table 3). Allopurinol reduced
ric acid by 46% from 0.59  0.09 mmol/l to 0.32  0.1
mol/l after 9 months of treatment. No correlation was
een between the change in LVM and the change in FMD,
Ix, PWV, or uric acid. All patients tolerated a daily dosage
f 600 mg of allopurinol except 1 patient who was left on
00 mg as she developed a rash while taking 600 mg.
iscussion
he main finding of this study is that high-dose allopurinol
educes LVM in patients with IHD and LVH who are on
urrent evidence-based optimal therapy. The secondary
ndings are that high-dose allopurinol reduces LV end-
ystolic volume and improves endothelial function and
rterial stiffness.
al Functionnd Endothelial Function
Allopurinol
(n  31)
Placebo
(n  29) p Value
5 13 3 15 0.59
4.2 8.0 1.4 8.0 0.2
1.5 11.0 3.6 8.5 0.17
0.76 5.0 2.6 4.0 0.61
0.64 2.0 0.25 2.0 0.097
0.82 1.8 0.69 2.8 0.017
0.96 3.0 0.8 3.1 0.036
1.4 2.8 1.1 3.3 0.002
3.4 5.1 1.0 6.3 0.14
2.8 5.1 0.9 7.0 0.02
0 (0.6 to 0.3) 0 (0.78 to 0.4) 0.85
.14 (0.8 to 0.3) 0.2 (1.25 to 0.4) 0.66
Figure 4 Effect of Allopurinol on the Change in AIx
This graph illustrates the effect of 6 months and 9 months of allopurinol (trian-
gles) or placebo (squares) treatment on the change in augmentation index
(AIx). Allopurinol significantly improved AIx after 9 months of therapy compared
with placebo (p  0.02). Data are expressed as mean  SEM.theliics a
0
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March 5, 2013:926–32 Allopurinol and LVH in Ischemic Heart DiseaseThe regression of LVH with allopurinol therapy seen in
this study is consistent with a recently published human
study showing that allopurinol regresses LVM in chronic
kidney disease (11). It is also consistent with 3 experimental
animal studies showing that xanthine oxidase inhibitors can
regress LVH (8–10). Our secondary findings are consistent
with a recently published study showing allopurinol to
improve FMD and AIx in very similar patients (12).
LVH is one of the most reliable surrogate markers we
have in cardiovascular medicine (18,19). In fact, the LIFE
study has shown that LVH regression per se can be
associated with reduced all-cause mortality (by 28%), car-
diovascular mortality (by 38%), sudden cardiac death (by
19%), myocardial infarction (by 15%), new congestive heart
failure (by 36%), new onset atrial fibrillation (by 12%), and
stroke (by 24%), and that these are all independent of any
change in BP (20–22). It remains to be seen whether
allopurinol-induced LVH regression can deliver anything
similar to these effects that were seen in the LIFE study.
What is the mechanism by which allopurinol regresses
LVM? One possibility could be that allopurinol reduces
oxidative stress which then regresses LVH (12,15,23).
However, in this study, allopurinol did not change oxidized
low-density lipoprotein levels. The second possible mecha-
nism is that allopurinol causes a significant reduction in AIx
and improved endothelial function without a significant
effect on BP suggesting improved arterial compliance,
which should also reduce cardiac afterload. A reduction in
AIx has been shown to be the best predictor of LVM
regression and this is the third study to show that allopuri-
nol reduces AIx (11,12,24). An effect on LV afterload is
supported by our significant reduction in end-systolic vol-
ume and nonsignificant reductions in both end-diastolic
volume and BNP. Although allopurinol had no effect on BP
in this and in other studies, this study was not powered to
detect an effect on BP as such and it remains possible that
some of the LVH regression seen here was due to subtle
changes in BP (12,15).
This new effect of allopurinol therapy on LVM regression
in patients with IHD is on top of a recently documented
anti-ischemic effect of allopurinol in angina patients (25).
The prospect of allopurinol reducing cardiovascular events is
enhanced by it having this dual effect of being both
anti-ischemic and reducing LVH. It is further enhanced by
data in this study showing that allopurinol improves vascular
function (FMD, AIx), reduces end-systolic volume, and
nearly reduces BNP. It is really this collection of favorable
changes in key surrogates that makes the case that allopuri-
nol might reduce cardiovascular events. Indeed, 2 other
small randomized controlled trials show this already (26,27).
We chose to prescribe allopurinol at a dosage of 600
mg/day as a previous study showed a strong dose-response
curve with a greater improved endothelial function with 600
mg/day compared to 300 mg/day (15). According to the
British National Formulary, allopurinol can be given up to
a dosage of 900 mg/day in the treatment of gout in patientswith normal renal function although doses of 100 to 300
mg/day are most commonly prescribed in clinical practice.
Study limitations. This is a single-center study with a
relatively small number of patients. It is almost inevitable
with so many demographic parameters that a few will by
chance be different at baseline, although few differences
were statistically significant. Additionally, the patients re-
cruited in this study were predominantly men and the
number of diabetic patients was low. Finally, although
significant, the effect of allopurinol on LVM is modest,
although it is similar in percentage terms to what was seen
between the 2 treatments in the echo substudy of the LIFE
trial (7).
Conclusions
Allopurinol reduces LVM in patients with IHD and LVH.
It also improves vascular function, LV afterload, and LV
end-systolic volume. This work increases the prospect that
allopurinol might reduce cardiovascular events or mortality
in patients with IHD. A large multicenter randomized
controlled trial is now indicated.
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